🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise worldwide, with data suggesting more than 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to results detailed in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The study included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in numerous developing nations.

Medical professionals on the front lines have voiced positive views. Having a easy-to-administer therapy like this is described as a "revolutionary step" for managing the epidemic. This is deemed essential to alleviate the strain of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.